Bit Bio Ltd
Mid-Sized Business (10-100M TTM Revenue)
bit.bio is a synthetic biology company providing human cells for research, drug discovery and cell therapy. The company applies a patented safe harbour gene-targeting approach, optimised inducible over expression (opti-ox™), to express transcription factor combinations that reprogram human induced pluripotent stem cells (iPSCs) into highly defined and mature human cell types. The company is marketing human iPSC-derived cell types and disease models for research use, and building a clinical pipeline.
The precise control of transcription factor expression in every stem cell leads to an entire culture converting to a defined cell type consistently and rapidly. This next generation precision reprogramming technology overcomes the challenges faced when using alternative cellular reprogramming methods or traditional directed differentiation, such as gene silencing, mixed cell populations, long protocol timelines, and lack of scalability.
opti-ox enabled cells are provided cryopreserved and are ready for experimentation within a few days. Cells are easy to use with our simple two-phase protocol and require only one open-source medium. They are suitable as models for research in molecular and cell biology, disease modelling, target validation and drug screening.
ioWild Type Cells™
Additional cell types in development, please contact us with your requests
ioDisease Model Cells™
ioDisease Model Cells are engineered to contain disease-relevant mutations. Each disease model cell can be used alongside a genetically matched wild-type control, forming an isogenic pair that enables scientists to make true comparisons in their data.
ioGlutamatergic Neurons HTT 50CAG/WT
ALS and frontotemporal dementia
ioGlutamatergic Neurons TDP-43 M337V homozygous and heterozygous
ioGlutamatergic Neurons MAPT P301S homozygous and heterozygous
ioGlutamatergic Neurons MAPT N279K homozygous and heterozygous
Parkinson’s and Gaucher diseases
ioGlutamatergic Neurons GBA null homozygous and heterozygous
ioGlutamatergic Neurons PRKN R275W homozygous and heterozygous
Duchenne muscular dystrophy
ioSkeletal Myocytes DMD Ex44 Deletion
ioSkeletal Myocytes DMD Ex52 Deletion
|bit.bio The Dorothy Hodgkin Building Cambridge, , CB22 3FH United Kingdom
If your organization has a Scientist.com marketplace, you can log in here to order products and services directly. If you're interested in ordering custom research services from suppliers in the Scientist.com network, book a meeting with our team here. To order products instantly, request access below.